Kangfang Biology (09926) plans to spend up to HK$200 million to repurchase shares, and the executive directors and senior management plan to increase their holdings.

Intelligence Finance APP News, Kangfang Biotech (09926) announced that on June 11, 2026, the board of directors of the company approved the use of up to 200 million Hong Kong dollars to buy back the company's ordinary shares in the open market. The purchase of shares will be executed by the trustees of the restricted share unit plan of the company in 2021. The board believes that the current trading price of the shares does not reflect the company's intrinsic value and business prospects, and now is a good opportunity to repurchase shares. The proposed share buyback demonstrates the board and management's confidence in the company's business outlook and prospects, and will benefit the company, creating value for shareholders. The proposed share buyback will be funded by the company's existing available cash resources.